Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5

Therapeutic Drug Monitoring

Volumn 26, Issue 6, 2004, Pages 600-608

  Picard, Nicolas ^a   Cresteil, Thierry ^b   Prémaud, Aurélie ^a   Marquet, Pierre ^a,c  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Cytochrome P450; LC MS MS; Metabolism; Mycophenolic acid

Indexed keywords

6 O NORMYCOPHENOLIC ACID; CYCLOSPORIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUCURONIDE; KETOCONAZOLE; MYCOPHENOLIC ACID; RECOMBINANT PROTEIN; TACROLIMUS; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANALYTICAL ERROR; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG URINE LEVEL; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; INTERMETHOD COMPARISON; KIDNEY CELL; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; OXIDATION KINETICS; PRIORITY JOURNAL; PROBABILITY;

CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; KIDNEY TRANSPLANTATION; MICROSOMES, LIVER; MYCOPHENOLIC ACID;

EID: 9644289307     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200412000-00004     Document Type: Article

References (25)

1. Ranson JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit. 1995;17:681-684.
2. Bullingham R, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
3. Nowak I, Shaw LM. Effects of mycophenolic acid glucuronides on inosine monophosphate dehydrogenase activity. Ther Drug Monit. 1997;19:358-360.
4. Smak Gregoor PJ, van Gelder T, Hesse CJ. et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant. 1999;14:706-708.
5. Van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119-128.
6. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy and analogous in vitro findings. Transpl Immunol. 1997;5:225-232.
7. Mojarrabi B, Mackenzie PI. The human UDP glucuronosyltransferase UGT1A10 glucuronidates mycophenolic acid. Biochem Biophys Res Commun. 1997;238:775-778.
8. Schütz E, Shipkova M, Armstrong VW, et al. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem. 1999;45:419-422.
9. Shipkova M, Armstrong VW, Wieland E, et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol. 1999;126:1075-1082.
10. Bradford MM. A rapid and sensitive method for the quantification of micrograms quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
11. Wen X, Wang JS, Backman JT, et al. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and 2C9, respectively. Drug Metab Dispos. 2002;30:631-635.
12. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos. 1995;23:154-158.
13. Ko JW, Desta Z, Soukhova NV, et al. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol. 2000;49:343-351.
14. Lacroix D, Sonnier M, Moncion A, et al. Expression of CYP3A in the human liver - evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem. 1997;247:625-634.
15. Sonnier M, Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem. 1998;251:893-898.
16. Treluyer JM, Gueret G, Cheron G, et al. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics. 1997;7:441-452.
17. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404-430.
18. Oellerich M, Armstrong VW, Kahan B, et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit. 1995;17:642-654.
19. Houston JB, Kenworthy KE. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos. 2000;28:246-254.
20. Witherow LE, Houston JB. Sigmoidal kinetics of CYP 3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J Pharmacol Exp Ther. 1999;290:58-65.
21. Domanski TL, Liu J, Harlow GR, et al. Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and α-naphthoflavone stimulation. Arch Biochem Biophys. 1998;350:223-232.
22. Fowler SM, Taylor JM, Friedberg T, et al. CYP3A4 active site volume modification by mutagenesis of leucine 211. Drug Metab Dispos. 2002;30:452-456.
23. Shipkova M, Armstrong VW, Oellerich M, et al. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit. 2003;25:1-16.
24. Hübner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit. 1999;21:536-539.
25. Pirsch J, Bekersky I, Vincenti F, et al. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharmacol. 2000;40:527-532.